Gene · 9113
NIH grants1,633
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 1,633
Download this page as JSON| Grant | Title | LATS1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA104509 | Molecular Mechanism of Leukemogenesis involving AML1-ETO | 1 | 2025 |
| R01CA163336 | Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data | 1 | 2025 |
| R01CA190558 | Mechanisms of Serrated Colon Tumor Suppression | 1 | 2025 |
| R01CA196643 | Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations | 1 | 2025 |
| R01CA197128 | Molecular mechanisms of focal adhesion kinase in promoting hepatocarcinogenesis | 1 | 2025 |
| R01CA204302 | Characterization of YAP as a rational companion target in lung cancer | 1 | 2025 |
| R01CA237159 | Mechanisms of pancreatic cancer initiation and progression from normal human pancreatic tissue | 1 | 2025 |
| R01CA252969 | Functional mechanisms and therapeutic potential of EAG channel regulators | 1 | 2025 |
| R01CA256188 | Probing cytosolic nucleic acid sensing pathways in cancer | 1 | 2025 |
| R01CA256791 | Role of Erbb3 kinase activity in colorectal tumorigenesis. | 1 | 2025 |
| R01CA256911 | Mitochondrial calcium signaling in pancreatic cancer metastasis and progression | 1 | 2025 |
| R01CA258449 | Identifying therapeutic options for intrahepatic cholangiocarcinoma | 1 | 2025 |
| R01CA260629 | Role of PTPRT in colon cancer progression and metastasis | 1 | 2025 |
| R01CA262536 | Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs | 1 | 2025 |
| R01CA262790 | The Role of Immature Tumor Subpopulations In Pediatric Rhabdomyosarcoma | 1 | 2025 |
| R01CA264320 | Mechanisms of PIK3CA helical domain mutations driving colorectal tumorigenesis | 1 | 2025 |
| R01CA266600 | EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | 1 | 2025 |
| R01CA266704 | Enhancing the Efficacy of Docetaxel in Prostate Cancer | 1 | 2025 |
| R01DA048153 | The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptor | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9113/grants?page=9